Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 3 |
Neoplasms | 2 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
AAV based gene therapy | 2 |
Diagnostic radiopharmaceuticals | 1 |
Target |
Mechanism EGFR modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseIND Application |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism mTOR inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseIND Application |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MAO-B inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date09 Dec 2021 |
Sponsor / Collaborator |
Start Date27 Oct 2021 |
Sponsor / Collaborator |
Start Date19 Jan 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
[18F]-D2-deprenyl ( MAO-B ) | Neuroinflammation More | Preclinical |
rAAV2-shmTOR-GFP (CuroGene Life Sciences/University of Ulsan) ( mTOR ) | Retinal Diseases More | Preclinical |
OBX1-012 ( EGFR T790M ) | Non-Small Cell Lung Cancer More | Preclinical |
rAAV2-sVEGFRv-1 (CuroGene Life Sciences/University of Ulsan) ( EGFR ) | Choroidal Neovascularization More | Preclinical |
IDF-11774 ( HIF-1α ) | Stomach Cancer More | Discovery |